Patient Profile
- Sex / Age:
- Male, 78 years
- Height / Weight:
- 174 cm / 71 kg (BMI 23.4)
- Reported symptoms:
- Easy bruising on forearms, one episode of gum bleeding while brushing, no overt bleeding
- Medications:
- Warfarin 5 mg daily (target INR 2.0–3.0), amiodarone 200 mg, atorvastatin 40 mg, recent course of trimethoprim-sulfamethoxazole for UTI (completed 4 days ago)
- History:
- Atrial fibrillation, hypertension, prior TIA — on long-term anticoagulation
Summary Overview
Comprehensive coagulation panel for a patient on chronic warfarin therapy. 5 parameters analyzed; 2 outside reference range. Findings consistent with warfarin over-anticoagulation (supratherapeutic INR), most plausibly precipitated by a recognized drug-drug interaction.
Calculated Indices & Risk Assessment
- INR target range:
- 2.0–3.0 (atrial fibrillation, no mechanical valve) [January CT, JACC 2019]
- Time-in-therapeutic-range concern:
- Current value substantially above target
- Bleeding risk classification:
- INR 4.5–10 without bleeding — moderate risk; reversal strategy depends on context [Holbrook A, CHEST 2012]
- HAS-BLED implication:
- Labile INR contributes 1 point — prior episodes warrant systematic review
Detailed Parameter Analysis
Differential Diagnosis — Conditions to Discuss with Your Physician
-
Drug-drug interaction-induced warfarin over-anticoagulationHigh
Recent TMP-SMX course is a well-established cause of marked INR rise in warfarin-treated patients (typical onset 3–7 days). Concurrent amiodarone is an independent potentiator [Hellfritzsch M, Drug Saf 2017; Holbrook A, CHEST 2012].
-
Reduced dietary vitamin K intakeModerate
Acute illness (UTI) commonly reduces appetite and vitamin K intake, which can independently raise INR. Worth asking about recent diet.
-
Hepatic dysfunctionLow
Normal fibrinogen and absence of clinical clues argue against, but liver function tests should be considered if INR does not normalize after warfarin hold.
-
Acquired factor deficiency / inhibitorLow
Rare but should be considered if INR remains elevated after withholding warfarin and supplementing vitamin K. Mixing studies would be the next step if pursued.
Analytical Summary & Recommendations
Clinical pattern
Asymptomatic supratherapeutic INR (5.8) in an elderly man on chronic warfarin, with two strong precipitating drug interactions in the recent timeline. No active bleeding; minor mucocutaneous signs (bruising, gum bleeding) are consistent with the INR level but not alarming.
Recommended next steps
- Hold next 1–2 warfarin doses and recheck INR in 24–48 hours [Holbrook A, CHEST 2012]
- Consider low-dose oral vitamin K (1–2.5 mg) — useful when INR > 4.5 without bleeding to reduce next-day INR
- Reassess weekly maintenance dose downward by 10–20% on resuming therapy
- Review complete medication list for further interacting agents at every encounter
- Consider switch to a direct oral anticoagulant (DOAC) if appropriate — fewer dietary and drug interactions; this should be a shared-decision conversation [January CT, JACC 2019]
- If any bleeding occurs (GI, urinary, intracranial symptoms): reversal strategy escalates to IV vitamin K and/or 4-factor PCC depending on severity [Frontera JA, Neurocrit Care 2016]
Monitoring
- INR recheck in 24–48 hours, then before resuming maintenance dose
- Watch for any new bleeding (red/black stool, hematuria, headache, increased bruising)
- Once stable, INR every 1–2 weeks for one month, then return to standard interval
Key Questions for Your Physician
- How many warfarin doses should I hold, and when should the next INR be checked?
- Should I take oral vitamin K now, and at what dose?
- Given the interaction with TMP-SMX and amiodarone, would a DOAC be a safer long-term option for me?
- What activities and medications should I avoid until my INR returns to range?
- How should future antibiotics be managed alongside my warfarin?
What This Means for You
Your blood is currently "thinned" too much by your warfarin (INR 5.8 versus a target of 2–3). The good news is that you are not actively bleeding, your platelets are normal, and your other clotting tests do not suggest any additional problem.
The most likely cause is the antibiotic you recently finished (TMP-SMX) combined with your long-standing amiodarone — both are well-known to amplify warfarin's effect. Reduced eating during the infection may have added to it.
Your physician will likely have you skip a dose or two, possibly give a small dose of vitamin K, and recheck your INR in a day or two. You should avoid bumps and falls, NSAIDs (ibuprofen, naproxen), and aspirin until things normalize.
Go to emergency care immediately for severe headache, vomiting blood, black stools, blood in urine, or any bleeding that does not stop — these are warning signs at this INR level.
High confidence in the over-anticoagulation pattern and drug-interaction etiology. The constellation of findings (isolated PT/INR rise out of proportion, normal fibrinogen, normal platelets, recognized interacting medications) makes alternative causes unlikely.
References
- Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: ACCP Guidelines. CHEST 2012;141(2 Suppl):e152S–e184S.
- January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update on the 2014 Guideline for the Management of Patients With Atrial Fibrillation. JACC 2019;74(1):104–132.
- Hellfritzsch M, Pottegård A, Pedersen AJ, et al. Topical antimicrobials and the risk of warfarin over-anticoagulation. Drug Saf 2017;40(10):901–911.
- Frontera JA, Lewin JJ, Rabinstein AA, et al. Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage. Neurocrit Care 2016;24(1):6–46.
- Schouten HJ, Geersing GJ, Koek HL, et al. Diagnostic accuracy of conventional or age adjusted D-dimer cut-off values in older patients with suspected venous thromboembolism: systematic review and meta-analysis. BMJ 2013;346:f2492.
- Garcia DA, Witt DM, Hylek E, et al. Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum. Ann Pharmacother 2008;42(7):979–88.